ProjectUpdated on 28 August 2025
Single Cell Drug Screening AI Platform
About
To investigate tumor heterogeneity, we have developed a single-cell culture device capable of isolating and individually culturing over 1.4 million single cells for high-throughput drug testing. Leveraging our proprietary AI model, we can accurately identify drug-resistant single cells, enabling further investigation and more precise prediction of treatment efficacy.
This platform accelerate cancer reserach, R&D progress for advanced therapeutics and predictive diagnostics for personalised cancer treatment.
Project Location
- China (Hong Kong)
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Bio-Tech
Total Project Value
- 2,500,001 to 5,000,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Minority Shareholdings
- Public–private partnership / Concession
- R&D Cooperation
Preferred Financing Model
- Equity
- Open for negotiation
Previous Funding Stage
- None
Main Service(s) Required
- Professional Services
Attached files
Organisation
Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)
Similar opportunities
Project
- Yes
- Debt
- None
- Equity
- Energy Storage
- Financial Services
- 50,000,001 USD or above
- 50,000,001 USD or above
- Feasibility Study Completed
- Energy and Natural Resources
- Private Equity & Venture Capital
- Public-Private Partnership Project
- Public–private partnership / Concession
recado Andrews
Director Invest SA at Department of Trade and Industry and Competition South Africa
Pretoria, South Africa
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Business Valuation
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- Institutional Investment
- Feasibility Study Completed
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
Novel Platinum-Based Drug Targeting Tumor Microenvironment (HJ-550 )
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Legal Advisory
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Investment Banking
- Business Valuation
- Corporate Services
- Open for Negotiation
- Professional Services
- Minority Shareholdings
- Feasibility Study Completed
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China